{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:53:45Z","timestamp":1775202825279,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128295","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:29:51Z","timestamp":1770935391000},"page":"128295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and safety of two doses of the four-component recombinant meningococcal B (4CMenB) vaccine in adults with immunodeficiency"],"prefix":"10.1016","volume":"76","author":[{"given":"L.","family":"Sticchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Domnich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Louth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Di Grazia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Icardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128295_bb0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128295_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clim.2012.09.007","article-title":"Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited","volume":"145","author":"Miller","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128295_bb0015","series-title":"Association with hypogammaglobulinemia Arch Intern Med","first-page":"664","article-title":"Meningococcemia caused by serogroup W135","volume":"141(5)","author":"Salit","year":"1981"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128295_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128295_bb0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/bmt.2016.181","article-title":"Bacterial meningitis in hematopoietic stem cell transplant recipients: a population-based prospective study","volume":"51","author":"van Veen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2026.128295_bb0030","series-title":"Manual for the Surveillance of Vaccine-Preventable Diseases [Internet]","article-title":"Chapter 8: Meningococcal Disease","author":"Centers for Disease Control and Prevention","year":"2024"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128295_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29678","article-title":"Multiregional MenB study group. Four-Component Recombinant Protein-Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy","volume":"6","author":"Lodi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128295_bb0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128295_bb0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14760584.2019.1578217","article-title":"Introduction of a second MenB vaccine into Europe \u2013 needs and opportunities for public health","volume":"18","author":"Findlow","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128295_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10719-021-09990-y","article-title":"Carbohydrate based meningococcal vaccines: past and present overview","volume":"38","author":"Berti","year":"2021","journal-title":"GlycoconjJ"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128295_bb0055","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/14760584.2021.1964962","article-title":"A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT","volume":"20","author":"Martinon-Torres","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128295_bb0060","author":"Presidenza del Consiglio dei Ministri Conferenza permanente per i rapporti tra lo stato le regioni e le province autonome"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128295_bb0065","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4250","article-title":"Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function","volume":"142","author":"Martin\u00f3n-Torres","year":"2018","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128295_bb0070","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hiv.13495","article-title":"The propositive study: immunogenicity and safety of a four-component recombinant protein-based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV","volume":"24","author":"Isitt","year":"2023","journal-title":"HIV Med"},{"issue":"12","key":"10.1016\/j.vaccine.2026.128295_bb0075","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cmi.2022.06.024","article-title":"Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients","volume":"28","author":"Robin","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.128295_bb0080","article-title":"Product review on the IMD serogroup B vaccine Bexsero\u00ae","volume":"18(1):2020043","author":"Deghmane","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128295_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4939-9202-7_12","article-title":"Meningococcal serogroup a, B, C, W, X, and Y serum bactericidal antibody assays","volume":"1969","author":"Lucidarme","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128295_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1473-3099(18)30048-3","article-title":"Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis","volume":"18","author":"Flacco","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128295_bb0095","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/hiv.13586","article-title":"Propositive follow-up: long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV","volume":"25","author":"San Francisco Ramos","year":"2024","journal-title":"HIV Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128295_bb0100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177182","article-title":"Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine","volume":"9","author":"Cotugno","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2026.128295_bb0105","author":"Australian immunization book"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128295_bb0110","first-page":"1","volume":"86","author":"Miller","year":"2023","journal-title":"J Inf Secur"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128295_bb0115","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Ljungman P; European conference on infections in leukaemia group. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European conference on infections in leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128295_bb0120","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ekir.2021.03.876","article-title":"Timing of COVID-19 vaccine in the setting of anti-CD20 therapy: a primer for nephrologists","volume":"6","author":"Kant","year":"2021","journal-title":"Kidney International Reports"},{"issue":"14","key":"10.1016\/j.vaccine.2026.128295_bb0125","first-page":"e1999","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128295_bb0130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"20","key":"10.1016\/j.vaccine.2026.128295_bb0135","doi-asserted-by":"crossref","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","article-title":"Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study","volume":"90","author":"Bar-Or","year":"2018","journal-title":"Neurology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:45:08Z","timestamp":1775195108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S0264410X26001039"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128295","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of two doses of the four-component recombinant meningococcal B (4CMenB) vaccine in adults with immunodeficiency","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128295"}}